Regorafenib-13C-d3

An internal standard for the quantification of regorafenib

此产品仅用于科学研究，我们不为任何个人用途提供产品和服务

库存: 现货

可选规格

包装

价格

促销价

数量
500ug

￥4075.00

3260.00

- +
1mg

￥7762.00

6210.00

- +

已选 0 种 0 瓶

金额: ￥0.00

首页收藏

货号: ajci64668
CAS: 2126178-55-8
别名: 瑞戈非尼-13C-D3,BAY 73-4506-13C,d3
分子式: C20[13C]H12D3ClF4N4O3
分子量: 486.8
纯度: >98%
溶解度: DMF: 30 mg/ml,DMSO: 30 mg/ml,Ethanol: 14 mg/ml
储存: Store at -20°C
库存: 现货

Background

Regorafenib-13C-d3 is intended for use as an internal standard for the quantification of regorafenib by GC- or LC-MS. Regorafenib is an orally bioavailable multi-kinase inhibitor with anticancer activity. It inhibits RET, C-RAF, VEGFR2, c-Kit, VEGFR1, and PDGFRβ with IC50 values of 1.5, 2.5, 4.2, 7, 13, and 22 nM, respectively. Regorafenib also inhibits B-RAF, VEGFR3, FGFR, and Tie2 (IC50s = 28, 46, 202, and 311 nM, respectively) as well as other kinases. In vivo, regorafenib (10 mg/kg) reduces tumor size in the MDA-MB-231 breast and 786-O renal cancer mouse xenograft models. It also reduces tumor microvessel area and inhibits tumor growth in a panel of mouse xenograft models. Formulations containing regorafenib have been used in the treatment of advanced gastrointestinal stromal tumors and metastatic colorectal cancer.